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Purpose: Patients with COPD might be particularly susceptible to hypoxia-induced autonomic 
dysregulation. Decreased baroreflex sensitivity (BRS) and increased blood pressure (BP) 
variability (BPV) are markers of impaired cardiovascular autonomic regulation and there is 
evidence for an association between decreased BRS/increased BPV and high cardiovascular 
risk. The aim of this study was to evaluate the effect of short-term exposure to moderate altitude 
on BP and measures of cardiovascular autonomic regulation in COPD patients.
Materials and methods: Continuous morning beat-to-beat BP was noninvasively measured 
with a Finometer® device for 10 minutes at low altitude (490 m, Zurich, Switzerland) and for 
2 days at moderate altitude (2,590 m, Davos Jakobshorn, Switzerland) – the order of altitude 
exposure was randomized. Outcomes of interest were mean SBP and DBP, BPV expressed as 
the coefficient of variation (CV), and spontaneous BRS. Changes between low altitude and 
day 1 and day 2 at moderate altitude were assessed by ANOVA for repeated measurements 
with Fisher’s exact test analysis.
Results: Thirty-seven patients with moderate to severe COPD (mean±SD age 64±6 years, 
FEV
1
 60%±17%) were included. Morning SBP increased by +10.8 mmHg (95% CI: 4.7–17.0, 
P=0.001) and morning DBP by +5.0 mmHg (95% CI: 0.8–9.3, P=0.02) in response to altitude 
exposure. BRS significantly decreased (P=0.03), whereas BPV significantly and progressively 
increased (P,0.001) upon exposure to altitude.
Conclusion: Exposure of COPD patients to moderate altitude is associated with a clinically 
relevant increase in BP, which seems to be related to autonomic dysregulation.
Clinical trial registration: ClinicalTrials.gov (NCT01875133).
Keywords: COPD, hypobaric hypoxia, baroreflex sensitivity, blood pressure variability
Plain language summary
Why was the study done? Hypoxia is a potent stressor for the cardiovascular system and patients 
with COPD might be particularly susceptible to hypoxia-induced autonomic dysregulation. 
What did the researchers do and find? When patients with moderate to severe COPD were 
exposed to hypobaric hypoxia at moderate altitude, they reacted with a clinically relevant increase 
of both blood pressure and heart rate accompanied by an increased blood pressure variability 
and a decreased baroreflex sensitivity.
What do these results mean? Disturbed autonomic cardiovascular regulation and increase in 
blood pressure and heart rate in response to hypoxia have important clinical implications for 
patients with COPD for altitude and air traveling and could explain part of the underlying patho-
physiology of the observed risk of cardiovascular events during an acute exacerbation of COPD. 
Introduction
COPD is characterized by progressive airflow limitation resulting from diffuse small 
airway disease and destruction of the lung parenchyma, leading to hypoxia and lung 
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hyperinflation as well as worsening dyspnea on exertion, 
wheezing, and cough.1 Many patients with COPD suffer from 
comorbidities such as cardiovascular disease and COPD is 
one of the leading causes of mortality worldwide.2
Barometric pressure and partial pressure of inspired and 
arterial oxygen fall with increasing altitude. Physiologic 
studies exposing healthy subjects to simulated altitude in the 
hypobaric chamber have shown an increase in sympathetic 
activity and autonomic dysregulation.3–5
Arterial oxygen partial pressure and saturation in patients 
with moderate to severe COPD are usually already decreased 
at rest at lowlands when compared with healthy subjects. 
Patients with COPD might develop severe hypoxemia at 
altitude that is further aggravated during physical activity.6 
Hypoxia-induced changes affect the cardiovascular system in 
particular. In addition, COPD is thought to be associated with 
impaired autonomic regulation,7,8 which has been shown to 
be improved by supplemental oxygen.9 Thus, COPD patients 
might be particularly susceptible to hypoxia-induced changes 
of cardiovascular regulation at altitude.10 In addition, other 
conditions of marked hypoxemia, such as acute exacerba-
tions of COPD, are associated with an increased risk for 
cardiovascular events in COPD.11
BP was shown to increase in healthy subjects at ascent 
to altitude.10,12 There is only very limited data from simu-
lated altitude13,14 and none from field studies on the effects 
of altitude exposure on BP or autonomic cardiovascular regu-
lation in COPD. However, considering the high prevalence 
of COPD, the number of patients with COPD traveling to 
altitude for recreational activities or pulmonary rehabilita-
tion in clinics located at moderate altitude is expected to 
be high. This implies a clinical importance of studying the 
effects of altitude exposure on pathophysiologic changes of 
the cardiovascular system in patients with COPD, who often 
suffer from comorbid cardiovascular disease.
Decreased BRS15,16 and increased BPV17–22 are established 
markers of impaired cardiovascular autonomic regulation. 
BPV underlies several cardiovascular control mechanisms 
and its increase is observed in conditions of impaired auto-
nomic regulation. Baroreceptors as part of the autonomic 
nervous system operate within seconds and modulate 
moment-by-moment variations in BP. The baroreflex works 
via a negative feedback loop: an increase in BP results 
in stretching the baroreceptors in the aortic arch and the 
carotid sinus that leads to lowering of the heart rate via the 
medulla oblongata and results in BP lowering by reducing 
cardiac output. Arterial baroreceptors (stretch receptors in 
the aortic arch and the carotid sinus) can be reset during, for 
example, exercise or sleep.23 Spontaneous BRS is assessed 
by analyzing the relation of BP and heart rate variations in 
the time or frequency domain.
Based on the knowledge of physiologic studies on the 
effects of hypobaric hypoxia in healthy subjects, we hypoth-
esized that acute altitude exposure of COPD patients will 
result in a relevant increase in BP by disturbed autonomic 
regulation of the cardiovascular system. To test this hypoth-
esis, we performed a randomized altitude trial investigating 
the effect of a short-term stay at moderate altitude on BP and 
measures of cardiovascular autonomic regulation in COPD 
patients living at low altitude.
Material and methods
Trial design and intervention
This study was performed as a substudy of a randomized 
trial on the effects of altitude exposure in COPD on exercise 
capacity that took place in Switzerland between May 2013 
(first recruitment) and December 2013 (last patient visit). 
Participants were examined at low altitude at 490 m a.s.l. 
(Zurich, barometric pressure [PB] 959 hPa) and at moderate 
altitude at 2,590 m a.s.l. (Davos Jakobshorn, PB 749 hPa) 
in random order (interval between assessments at different 
altitude levels $2 weeks) under a standardized environmental 
condition (temperature, position, time of the day). Block 
randomization was performed by choosing a time schedule 
for the assessments being blinded to the order of altitudes.24 
The data analyzer was blinded to the group allocation. 
Transport between study locations was by train and cable 
car. Outcome assessments were performed on 2 consecutive 
days to study a potential acclimatization effect by physi-
ologic adaptation. The study protocol was approved by the 
local ethics committee (EK-2013–0088) and registered at 
ClinicalTrials.gov (NCT01875133). Written informed con-
sent was obtained from each participant before inclusion. The 
study was conducted according to the Declaration of Helsinki.
Participants
Patients aged 18–75 years who were diagnosed with moderate 
to severe COPD (COPD Gold grade 2–3) and were living 
at low altitude (,800 m a.s.l.) were included. Patients 
with mild (FEV
1
 .80% predicted) or very severe COPD 
(FEV
1
 ,30% predicted, paO
2
 at 490 m ,7.3 kPa [55 mmHg], 
paCO
2
 at 490 m .6.7 kPa [50 mmHg]), requiring supple-
mental oxygen at low altitude, currently suffering from a 
COPD exacerbation, currently smoking .20 cigarettes/day, 
with poorly controlled cardiovascular disease or with known 
altitude intolerance were excluded. Low and moderate 
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altitude settings were the Sleep Unit of the University 
Hospital of Zurich and a cable car station in Davos 
Jakobshorn, respectively. The moderate altitude study loca-
tion of 2,590 m (PB 749 hPa) corresponds to many mountain 
huts as well as to cabin pressure during air travel.
Sample size estimation based on expected minimally 
important differences in the primary outcome of the main 
trial (six-minute walk test)25,26 and data from previous alti-
tude trials.27
Outcomes
The main outcome of interest was the change in both morn-
ing SBP and morning DBP. Other outcomes of interest were 
spontaneous BRS and BPV, both as measures of sympathova-
gal function. Heart rate was an additional outcome.
Continuous morning beat-to-beat BP was noninvasively 
measured by a physician with the Finometer® MIDI device 
(Finapres Medical Systems B.V., Amsterdam, the Netherlands) 
for 10 minutes in the early morning with the patient in supine 
position after a period of rest of .10 minutes in a quiet room 
with stable temperature and lightening. Application of the 
Finapres (FINger Arterial PRESsure) technique28 allows 
noninvasive continuous measurement of finger arterial 
pressure by a servo-plethysmo-manometer with infra-red 
transmission whereby volume fluctuations serve as surro-
gate of intra-arterial BP. It provides accurate assessments 
of short-term changes of BP as previously described and 
validated.29 BPV was expressed as the CV (ratio of the SD to 
the mean) of continuous beat-to-beat BP. BRS was automati-
cally quantified with dedicated software (BeatScope Easy 
v1.1a, ADInstruments, Sydney, Australia).30
statistical methods
Normality of distribution was tested by Kolmogorov-Smirnov 
tests. Normally distributed data are described as mean (SD) 
and nonnormally distributed data as median (IQR). Changes 
between low altitude and day 1 and day 2 at moderate altitude 
were assessed by ANOVA for repeated measurements with 
Fisher post hoc analysis. The average of the two measure-
ments at low altitude (day 1 and day 2) was compared with 
the measurements at day 1 and day 2 at moderate altitude. 
Statistical significance level was set at alpha ,0.05. In addi-
tion to univariate regression, multivariate regression analysis 
was used to study the relationship between changes in BP, 
BPV and BRS and clinical characteristics (airflow limitation 
at baseline, sleep apnea severity at altitude, hypoxemia, and 
exercise desaturation) correcting for potential confounders 
(age and baseline value of the actual variable, eg, BP or BRS). 
Statistical analysis was performed with Statistica version 6 
software (StatSoft, Inc., Tulsa, OK, USA).
Ethics statement
The study was approved by the Ethics Committee of the 
Canton of Zurich, Switzerland (Kantonale Ethikkommission 
Zürich); registration reference EK-2013 – 0088.
Results
Participants
Forty patients with moderate to severe COPD were randomly 
assigned to the order of altitude exposure. Three participants 
refused to take part in the assessments on the other altitude 
level and withdrew consent. Finometer measurements at both 
altitudes were available for 37 patients. The study flowchart is 
shown in Figure 1. Patient characteristics are shown in Table 1.
Main outcome of interest
Morning SBP increased by +10.8 mmHg (95% CI: 4.7–17.0, 
P=0.001) and morning DBP by +5.0 mmHg (95% CI: 0.8–9.3, 
P=0.02) at the first day of altitude exposure (Table 2). On 
the second day of the altitude sojourn, BP slightly decreased, 
but SBP was still statistically significantly elevated when 
compared to baseline (Table 2, Figure 2).
Other outcomes of interest
BRS significantly decreased (-3.0 msec/mmHg, 95% 
CI: -5.7 to -0.3, P=0.03) at moderate altitude, whereas 
BPV significantly and progressively increased (+1.8%, 95% 
CI: 0.9–2.6, P,0.001) upon ascent to moderate altitude 
(Table 2, Figure 2). Heart rate increased by +6.7 bpm (95% 
CI: 4.3–9.1, P,0.001).
Predictors of BP and autonomous 
response to altitude
In multivariate regression modelling including age, severity 
of airflow limitation (FEV
1
 percent predicted), oxygenation 
(paO
2
), oxygen desaturation during exercise at altitude, and 
severity of sleep-disordered breathing at altitude (oxygen 
desaturation index), only severity of airflow limitation and 
desaturation during exercise were independently associated 
with the response of blood pressure and its variability to alti-
tude exposure. Within the multivariate model, no independent 
association of these parameters with BRS were identified. 
Changes in BRS were significantly correlated with intermit-
tent nocturnal hypoxia (oxygen desaturation index, r=-0.43, 
P=0.025) but not with daytime oxygen saturation at altitude 
in univariate regression.
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Figure 1 Study flowchart.
Discussion
This trial has shown that acute exposure of patients with 
moderate to severe COPD to moderate altitude results in a 
clinically relevant increase in BP. This was accompanied 
by a significant increase in BPV and a decrease in BRS, 
indicating autonomic dysregulation as the cause of the BP 
increase. Although an increase in cardiac output and in BP 
are a physiologic response to hypoxia, the increase in heart 
rate and BP seen in COPD patients was more extensive than 
in healthy young subjects exposed to the same level of hypo-
baric hypoxia.31 The significantly more pronounced increase 
in SBP and heart rate in this COPD cohort compared to 
healthy controls31 upon exposure to moderate altitude (same 
location, same environmental conditions) point towards a 
higher susceptibility of COPD patients to respond to hypo-
baric hypoxia with an increase in sympathetic activity.
There were moderate linear relationships between mea-
sures of exercise hypoxemia at altitude and changes in BP and 
its variability in response to altitude exposure. This finding 
leads to the conclusion that an increase in both BP and BPV 
may also be expected in other conditions of marked hypoxia 
in COPD patients, such as during a COPD exacerbation. 
Whereas the change in BRS was not associated with day-
time hypoxemia at altitude, BRS negatively correlated with 
intermittent nocturnal hypoxia, meaning that concomitant 
sleep apnea might impair BRS.
BRS- and BPV-values in our patients were within the 
normal limit and BP was in the normotensive range at low 
altitude. BRS significantly declined to pathologic values 
upon altitude exposure. Mean BRS in healthy subjects aged 
50–60 years was 6.8 ms/mmHg (95% CI: 6.2–7.3 ms/mmHg) 
in a large population-based study and was shown to decline 
with age.30 Normal values of short-term BPV are expected 
to be ~6%–8%.32
There is evidence of an association between increased 
BPV – visit-to-visit variability20,21 or variability during 
24 h BP monitoring22 – and high cardiovascular risk. Less 
is known on beat-to-beat BPV. The baroreceptor reflex is 
responsible for fast, short-term, neuronal regulation of BP. 
However, beat-to-beat BPV was shown to be associated with 
visit-to-visit BPV despite different and complex underlying 
mechanisms.33,34
Autonomic regulation is influenced by hypoxemia and 
hypocapnia. In our patients, both paO
2
 and paCO
2
 from 
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Table 1 Patient characteristics
Characteristics COPD patients at 
baseline (n=37)
age (years) 64.3 (6.3)
Male, n (%) 26 (79)
BMI (kg/m2) 26.3 (4.8)
FeV1 (l) 1.7 (0.7)
FeV1 (% predicted) 60 (17)
rV/TlC 47.9 (8.3)
rV/TlC (%) 122 (21)
TlCO(hb) (mmol/min/kPa) 5.7 (2.3)
TlCO(hb) (%) 64 (20)
paO2 (kPa) 8.9 (1.2)
paCO2 (kPa) 5.5 (0.6)
spO2 (%) 93.5 (1.8)
saBa, n (%) 10 (27)
saMa, n (%) 2 (5)
laBa, n (%) 30 (81)
laMa, n (%) 29 (78)
ICs, n (%) 23 (62)
hypertension, n (%) 23 (62)
Beta blocker, n (%) 7 (19)
angiotensin converting enzyme inhibitor or 
angiotensin receptor blocker, n (%)
18 (49)
Other antihypertensive drugs (calcium 
antagonist or diuretic), n (%)
16 (43)
Cardiovascular disease, n (%) 4 (11)
Diabetes mellitus type 2, n (%) 1 (3)
Note: Data are given as mean (sD) unless otherwise mentioned.
Abbreviations: BMI, body-mass-index; ICs, inhaled corticosteroid; laBa, inhaled 
long-acting beta-agonist; laMa, inhaled long-acting muscarinic antagonist; paCO2, 
arterial partial pressure of carbon dioxide; paO2, arterial partial pressure of oxygen; 
rV, residual vol; saBa, inhaled short-acting beta-agonist; saMa, inhaled short-
acting muscarinic antagonist; spO2, finger pulse oximeter-based oxygen saturation; 
TlC, total lung capacity; TlCO(hb), carbon monoxide transfer factor adjusted 
for hemoglobin.
Table 2 anOVa for repeated measurements
Outcome 490 m, 
n=37
2,590 m 
day 1, n=37
2,590 m 
day 2, n=37
Mean sBP (mmhg) 122.4 (21.5) 133.2 (21.6)* 131.1 (16.5)*
Mean DBP (mmhg) 65.4 (13.1) 70.4 (9.1)* 69.0 (9.5)
CV sBP (%) 6.6 (1.7) 7.4 (1.7) 8.3 (2.0)*,^
CV DBP (%) 6.9 (2.3) 7.6 (2.5) 8.7 (2.4)*,^
Brs (msec/mmhg) 7.8 (9.1) 4.8 (3.2)* 4.9 (2.7)*
heart rate (bpm) 68.5 (8.3) 75.2 (10.0)* 73.2 (7.9)*,^
Notes: Data are presented as mean (sD). *P,0.05 vs 490 m. ^P,0.05 vs 2,590 m 
day 1.
Abbreviations: BRS, baroreflex sensitivity; CV, coefficient of variation.
arterial blood gas analysis significantly decreased upon 
altitude exposure (paO
2
 from 8.2±1.9 to 6.0±1.1 kPa, and 
paCO
2
 from 5.6±0.9 to 4.7±0.5 kPa).35 In the same study 
population, exposure to moderate altitude was shown to 
be associated with a reduced oxygen uptake and reduced 
cerebral tissue oxygenation when compared to low altitude.35 
Echocardiography in this population revealed a reduction 
of parameters assessing right ventricular function and 
an increase in calculated mean pulmonary artery pressure in 
response to moderate altitude that were mainly interpreted 
as a consequence of hypoxic pulmonary vasoconstriction.36 
Of possible pathophysiologic importance to the BP increase 
at moderate altitude is the development of moderate to 
severe central sleep apnea at 2,590 m, additionally result-
ing in increased sympathetic activity due to the intermittent 
hypoxia and disturbed sleep.24 However, sleep apnea severity 
expressed as the apnea–hypopnea index or oxygen desatu-
ration index was not independently associated with the BP 
response to altitude exposure. Nevertheless, known breathing 
disturbances during sleep at altitude due to frequent central 
events may play a role in the observed autonomic changes.
In accordance with our finding, Kourtidou-Papadeli 
et al14 have shown a statistically significant increase in SBP 
in patients with COPD and a less pronounced increase in 
SBP in healthy subjects exposed to hypobaric hypoxia by 
simulated altitude. Our findings of a slight decrease in BP 
over days of the altitude sojourn is in line with the finding 
of Kanstrup et al,37 which showed a BP increase upon ascent 
followed by a slight decrease on day 2 at altitude.
Patakas et al7 found a lower BRS after injection of 
phenylephrine in COPD patients than in healthy controls. 
In their study, pulmonary artery pressure during right heart 
catheterization showed the strongest association with BRS. 
They concluded that blunted baroreceptor response to phar-
macologically induced BP changes in COPD is partially 
related to pulmonary hypertension and partly to the central 
effects of hypoxia and hypercapnia.7 Mazzeo et al38 found an 
increase in urinary and arterial epinephrine at initial exposure 
to altitude (4,300 m) in healthy men and observed a decrease 
after 3 weeks of acclimatization.
Sympathetic hyperactivation along with compromise 
in parasympathetic activity was found in healthy subjects 
exposed to high altitude at 6 and 18 months compared to 
baseline at low altitude. However, a reduction of sympa-
thetic activity and an increased parasympathetic response 
was observed over time at altitude suggesting a partial 
acclimatization.39
Our findings are the first field study data on the effect of 
altitude on measures of autonomic cardiovascular regulation 
in COPD patients. This study provides an explanation for the 
observed increase in BP by showing autonomic dysregulation 
in COPD patients exposed to altitude.
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Figure 2 anOVa of repeated measurements.
Notes: Comparison of (A) sBP, (B) DBP, (C) blood pressure variability, and (D) spontaneous baroreflex sensitivity (BRS) between low altitude and day 1 and day 2 at 
moderate altitude. Vertical bars denote 95% CIs. *P,0.05 vs 490 m. ^P,0.05 vs 2,590 m day 1.
A strength of the study is the randomization of altitude 
exposure, therefore avoiding influence of adaption to the 
measurements taken. Knowledge on the cardiovascular 
effects of exposing COPD to the altitude of 2,590 m is of 
clinical importance since barometer pressure at this altitude is 
comparable to that of many mountain huts and to the maximal 
altitude equivalent for commercial air flight. The findings on 
the effect of hypoxia on cardiovascular autonomic regulation 
have important implications for other conditions of acutely 
aggravated hypoxia, eg, acute exacerbations of COPD.
Limitations
A limitation for the interpretation of secondary outcomes 
is the fact that the sample size was not powered to analyze 
independent associations between the main outcomes and 
clinical predictors and some associations may not have 
been identified – these analyses are purely explorative. 
In addition, the sample size limits subgroup analyses on the 
role of antihypertensive drugs and some of the statistical 
approaches (eg, multivariable regression). Another limita-
tion of the study is a potential influence of the results by 
requirement of supplemental oxygen at moderate altitude in 
five patients. However, oxygen was not supplemented during 
the outcome assessments. The potential influence of anticho-
linergic and beta-adrenergic agents on autonomic regulation 
was not studied in this trial. However, daily tiotropium for 
3 months did not affect heart rate variability in 70 COPD 
patients.40 Although the findings in this COPD cohort can 
be compared to healthy controls in a previous study,31 the 
control subjects were not matched in terms of age or the 
presence of hypertension, which limits the interpretation 
of such a comparison.
Future altitude trials are warranted to assess the role of 
supplemental oxygen and therefore reduction of hypoxemia 
at altitude on BP and measures of autonomic cardiovas-
cular regulation.
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Conclusion
Short-term exposure of patients with COPD to moderate 
altitude is associated with a clinically relevant increase in 
BP, which is related to autonomic dysregulation. This finding 
should be considered when COPD patients with cardiovas-
cular comorbidities are counselled on vacation or rehabilita-
tion at altitude or for air traveling and in other conditions of 
hypoxemia such as acute exacerbations of COPD.
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